These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 31799745)

  • 41. MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer.
    Andolfi C; Bartolini C; Morales E; Gündoğdu B; Puhr M; Guzman J; Wach S; Taubert H; Aigner A; Eder IE; Handle F; Culig Z
    Endocrinology; 2024 Aug; 165(10):. PubMed ID: 39253786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
    Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
    Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy.
    Quick J; Santos ND; Cheng MHY; Chander N; Brimacombe CA; Kulkarni J; van der Meel R; Tam YYC; Witzigmann D; Cullis PR
    J Control Release; 2022 Sep; 349():174-183. PubMed ID: 35780952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
    Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
    Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model.
    Mout L; de Wit R; Stuurman D; Verhoef E; Mathijssen R; de Ridder C; Lolkema M; van Weerden W
    EBioMedicine; 2018 Jan; 27():182-186. PubMed ID: 29276148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer.
    Cao B; Qi Y; Yang Y; Liu X; Xu D; Guo W; Zhan Y; Xiong Z; Zhang A; Wang AR; Fu X; Zhang H; Zhao L; Gu J; Dong Y
    PLoS One; 2014; 9(11):e111201. PubMed ID: 25375370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer.
    Martin SK; Pu H; Penticuff JC; Cao Z; Horbinski C; Kyprianou N
    Cancer Res; 2016 Feb; 76(4):912-26. PubMed ID: 26645563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
    Mostaghel EA; Morgan A; Zhang X; Marck BT; Xia J; Hunter-Merrill R; Gulati R; Plymate S; Vessella RL; Corey E; Higano CS; Matsumoto AM; Montgomery RB; Nelson PS
    PLoS One; 2014; 9(10):e111545. PubMed ID: 25356728
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
    de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
    Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer.
    Ushijima M; Shiota M; Matsumoto T; Kashiwagi E; Inokuchi J; Eto M
    Cancer Sci; 2022 May; 113(5):1731-1738. PubMed ID: 35118769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.
    Reddy V; Iskander A; Hwang C; Divine G; Menon M; Barrack ER; Reddy GP; Kim SH
    PLoS One; 2019; 14(5):e0211090. PubMed ID: 31083651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
    Isharwal S; Modi S; Arora N; Uhlrich C; Giri B; Barlass U; Soubra A; Chugh R; Dehm SM; Dudeja V; Saluja A; Banerjee S; Konety B
    Prostate; 2017 May; 77(6):584-596. PubMed ID: 28144973
    [TBL] [Abstract][Full Text] [Related]  

  • 53. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.
    Szafran AT; Stephan C; Bolt M; Mancini MG; Marcelli M; Mancini MA
    Prostate; 2017 Jan; 77(1):82-93. PubMed ID: 27699828
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
    Antonarakis ES
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
    Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AR-V7 and prostate cancer: The watershed for treatment selection?
    Ciccarese C; Santoni M; Brunelli M; Buti S; Modena A; Nabissi M; Artibani W; Martignoni G; Montironi R; Tortora G; Massari F
    Cancer Treat Rev; 2016 Feb; 43():27-35. PubMed ID: 26827690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intracrine androgen biosynthesis in renal cell carcinoma.
    Lee GT; Han CS; Kwon YS; Patel R; Modi PK; Kwon SJ; Faiena I; Patel N; Singer EA; Ahn HJ; Kim WJ; Kim IY
    Br J Cancer; 2017 Mar; 116(7):937-943. PubMed ID: 28253524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.